ILLUSION OF REPERFUSION - DOES ANYONE ACHIEVE OPTIMAL REPERFUSION DURING ACUTE MYOCARDIAL-INFARCTION (CIRCULATION, PG 1792, JUNE 1993)

被引:202
作者
LINCOFF, AM [1 ]
TOPOL, EJ [1 ]
机构
[1] CLEVELAND CLIN FDN, DEPT CARDIOL, F25, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA
关键词
THROMBOLYSIS; REOCCLUSION; REPERFUSION; CLINICAL PROGRESS SERIES;
D O I
10.1161/01.CIR.88.3.1361
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombolytic therapy significantly improves the natural history of acute myocardial infarction, but recent data suggest that current reperfusion strategies have yet to realize the maximum potential for reduction of mortality and salvage of ventricular function. Coronary patency rates as high as 85% assessed by angiography 90 minutes after initiation of treatment greatly overestimate the efficacy of thrombolytic regimens, as this conventional angiographic ''snapshot'' view does not satisfactorily reflect the dynamic processes of coronary artery recanalization and reocclusion or the adequacy of myocardial perfusion. In fact, only the unusual patient appears to achieve optimal reperfusion for acute myocardial infarction, with a substantial deterioration of benefit in many patients due to insufficiently early or rapid recanalization, incomplete patency with TIMI grade 2 flow or critical residual coronary stenoses, absence of myocardial tissue reflow despite epicardial artery patency, intermittent coronary patency, subsequent reocclusion, or reperfusion injury. Recently developed techniques to critically assess the quality of reperfusion, coupled with the introduction of novel pharmacological agents and an improved understanding of the roles and mechanisms of existing thrombolytic and adjunctive drugs, have provide the opportunity to overcome many of the present limitations of reperfusion therapy. Emerging strategies to achieve optimal reperfusion are directed at enhancement of the velocity and quality of thrombolysis, amelioration of the adverse effects of reperfusion, and use of alternative pathways to myocardial salvage.
引用
收藏
页码:1361 / 1374
页数:14
相关论文
共 125 条
[1]  
ANDERSON JL, 1984, CIRCULATION, V70, P606, DOI 10.1161/01.CIR.70.4.606
[2]  
[Anonymous], 1988, LANCET, V2, P349
[3]  
[Anonymous], 1989, NEW ENGL J MED, V320, P618
[4]  
[Anonymous], 1990, Lancet, V336, P65
[5]   TISSUE PLASMINOGEN-ACTIVATOR - TORONTO (TPAT) PLACEBO-CONTROLLED RANDOMIZED TRIAL IN ACUTE MYOCARDIAL-INFARCTION [J].
ARMSTRONG, PW ;
BAIGRIE, RS ;
DALY, PA ;
HAQ, A ;
GENT, M ;
ROBERTS, RS ;
FREEMAN, MR ;
BURNS, R ;
LIU, P ;
MORGAN, CD .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1989, 13 (07) :1469-1476
[6]   CORRELATION BETWEEN LEVEL OF HEPARINIZATION AND PATENCY OF THE INFARCT-RELATED CORONARY-ARTERY AFTER TREATMENT OF ACUTE MYOCARDIAL-INFARCTION WITH ALTEPLASE (RT-PA) [J].
ARNOUT, J ;
SIMOONS, M ;
DEBONO, D ;
RAPOLD, HJ ;
COLLEN, D ;
VERSTRAETE, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 20 (03) :513-519
[7]   INTRACORONARY ADENOSINE ADMINISTERED AFTER REPERFUSION LIMITS VASCULAR INJURY AFTER PROLONGED ISCHEMIA IN THE CANINE MODEL [J].
BABBITT, DG ;
VIRMANI, R ;
FORMAN, MB .
CIRCULATION, 1989, 80 (05) :1388-1399
[8]   LIMITATION OF MYOCARDIAL REPERFUSION INJURY BY INTRAVENOUS PERFLUOROCHEMICALS - ROLE OF NEUTROPHIL ACTIVATION [J].
BAJAJ, AK ;
COBB, MA ;
VIRMANI, R ;
GAY, JC ;
LIGHT, RT ;
FORMAN, MB .
CIRCULATION, 1989, 79 (03) :645-656
[9]   IMPROVED SURVIVAL BUT NOT LEFT-VENTRICULAR FUNCTION WITH EARLY AND PREHOSPITAL TREATMENT WITH TISSUE PLASMINOGEN-ACTIVATOR IN ACUTE MYOCARDIAL-INFARCTION [J].
BARBASH, GI ;
ROTH, A ;
HOD, H ;
MILLER, HI ;
MODAN, M ;
RATH, S ;
ZAHAV, YH ;
SHACHAR, A ;
BASAN, S ;
BATTLER, A ;
RABINOWITZ, B ;
KAPLINSKY, E ;
SELIGSOHN, U ;
LANIADO, S .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (03) :261-266
[10]   EFFECT OF HEPARIN ON CORONARY ARTERIAL PATENCY AFTER THROMBOLYSIS WITH TISSUE PLASMINOGEN-ACTIVATOR IN ACUTE MYOCARDIAL-INFARCTION [J].
BLEICH, SD ;
NICHOLS, TC ;
SCHUMACHER, RR ;
COOKE, DH ;
TATE, DA ;
TEICHMAN, SL .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (20) :1412-1417